| |
|
|
|
 Cam L. Garner
Chairman
Cam Garner is one of our co-founders and has served as Chairman of our board of directors since March 2008. Garner is a pharmaceutical executive with over 30 years of diverse experience in the healthcare industry ranging from diagnostics and devices to pharmaceuticals. He was part of the senior management team that built Hybritech, Inc.
Garner served as Chief Executive Officer of Dura Pharmaceuticals, Inc. from 1989-1995 and Chairman and CEO from 1995-2000. During his tenure, Dura’s annual revenues grew from $2 million to over $300 million. Dura was sold in November 2000, for $1.8 billion to Elan Corporation.
Garner has co-founded several specialty pharmaceutical companies including Cadence Pharmaceuticals, Somaxon Pharmaceuticals, Verus Pharmaceuticals, Zogenix, Evoke Pharma, Elevation Pharmaceuticals, DJ Pharma and Xcel Pharmaceuticals. He currently serves as Chairman of Cadence, Zogenix, Evoke and Elevation and served as Chairman of DJ Pharma and Xcel Pharmaceuticals until they were sold. Garner also serves on the board of directors of Aegis Therapeutics. Additionally, he is currently involved in several charitable organizations.
Garner earned his M.B.A. from Baldwin-Wallace College and his B.A. from Virginia Wesleyan College.
|
|
|
 James C. Blair, Ph.D.
Director
Jim Blair, Ph.D. has been a Partner of Domain Associates since its founding in 1985. Present board memberships include Cadence Pharmaceuticals, Cell Biosciences, CoDa Therapeutics, Five Prime Therapeutics, GenVault, Helixis, Meritage Pharma, Microchip Biotechnologies, NeuroPace and Zogenix. Blair has over 35 years experience with venture and emerging growth companies. In the course of this experience, he has been involved in the creation and successful development at the board level of over 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, NuVasive, Pharmion and Volcano. A former managing director of Rothschild Inc., Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies.
From 1961 to 1969, Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship. He currently serves on the board of directors of the Prostate Cancer Foundation, and he is on the advisory boards of the Department of Molecular Biology at Princeton University, the Department of Biomedical Engineering at the University of Pennsylvania, and the Board of Counselors of the USC Stevens Institute for Innovation.
Blair earned his B.S.E. from Princeton University and his M.S.E. and Ph.D. from the University of Pennsylvania. |
|
|
|
 Kenneth J. Widder, M.D.
Director
Ken Widder, M.D. has 25 years of experience working with biomedical companies. He has founded seven companies and was chairman/CEO of five of them. Widder is currently a partner at Latterell Venture Partners. His last company, Sytera Inc. merged with Sirion Therapeutics, an ophthalmology specialty pharmaceutical company.
Prior to Sytera, Widder founded and was CEO of NovaCardia, a cardiovascular disease company that was acquired by Merck. Prior to NovaCardia, he founded and was Chairman/CEO of Santarus, which developed and currently markets Zegerid™, a rapid onset proton pump inhibitor for esophageal reflux disease. Additionally, Widder was Chairman and CEO of Converge Medical, a medical device company developing a sutureless anastamosis system for vein grafts in coronary by-pass surgery.
Widder started his career as a founder, Chairman and CEO of Molecular Biosystems, where he was responsible for the development and approval of Albunex™ and Optison™, the first two ultrasound contrast agents to be approved in the U.S. He holds an M.D. from Northwestern University and trained in pathology at Duke University. Widder is an inventor on more than 30 patents and patent applications and has authored or co-authored more than 25 publications.
|
|
 Elaine M. Phillips, Ph.D.
President & CEO
Elaine Phillips, Ph.D. is one of our co-founders and has served as President and CEO and a member of our board of directors since March 2008. Phillips has over 17 years of experience in pharmaceuticals and drug delivery for both commercialized products and products in development. Prior to joining Meritage, Phillips was Senior Vice President of Technical Operations at Verus Pharmaceuticals, Inc., where she was responsible for the technical aspects of products in Verus’ portfolio including the commercialization of the Twinject® epinephrine auto-injector.
Prior to joining Verus, Phillips was a member of ProPharmaCon, LLC providing drug development consulting and contract services to clients for products across the development cycle. She was employed at Dura Pharmaceuticals (then Elan) from 1997 to 2001 where she focused on the delivery of proteins and peptides to the lung. Prior to that, Phillips was in the Department of Pharmaceutics at Hoffmann-La Roche for five years where she had various functional responsibilities ranging from pre-formulation and aerosol formulation development, solid state characterization and package development. She has publications and patent applications in the fields of crystal growth, device design, drug delivery, controlled-release and pharmaceutical applications of super critical fluids.
Phillips has a Ph.D. in pharmaceutics from Virginia Commonwealth University, a B. SC. in chemical engineering from the University of Kentucky and has performed post-doctoral studies in pharmaceutical chemistry at the University of Kansas. |
|
|
|
|
|
|
|
|
|
|
